$FOXO

FOXO TECHNOLOGIES INC. ANNOUNCES INTENTION TO SPIN OFF EPIGENETICS SUBSIDIARY

WEST PALM BEACH, FLORIDA, July 18, 2025 ( GLOBE NEWSWIRE ) -- FOXO Technologies Inc. ( NYSE American: FOXO ) ( "FOXO" or the "Company" ) , today announced that its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary that is focused on the development of its ...

Original reporting
GlobeNewswire · FOXO Technologies Inc.
Published Jul 18, 2025, 11:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 18, 2025, 11:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FOXO TECHNOLOGIES INC. ANNOUNCES INTENTION TO SPIN OFF EPIGENETICS SUBSIDIARY — source image
Decision brief

The 30-second read

$FOXOBullishMed
01

Why it matters

The move is likely to be viewed positively by investors seeking clarity and growth potential, but actual market impact depends on investor perception and broader market conditions.

02

Market read

The announcement is relevant to biotech investors and may influence the company's stock performance in the short to medium term.

03

What to watch

Market reaction could be muted if the spin-off is perceived as a routine corporate action or if broader market conditions are unfavorable.

Timing: Immediate, as the news is recent and may influence trading today.

Background

FOXO Technologies Inc. is pursuing a spin-off of its FOXO Labs subsidiary focused on epigenetics, aiming to unlock value and improve operational focus.

Company-level read

Ticker impact

$FOXOBullishMedium confidence
Context

Primary focus due to company's strategic move to spin off a subsidiary.

Expected impact

Moderate upward movement expected in the short to medium term.

Evidence & confidence

Spin-offs often lead to increased focus and valuation clarity for the core company, which can positively influence stock price. However, market reaction depends on investor perception of the spin-off's strategic value.

Market effects

Potential positive sentiment in the biotech and biotech-related sectors due to increased focus and resource allocation.

Limited regional impact, primarily affecting investors and markets in the U.S.

Moderate, as the company is listed on a U.S. exchange and the news may influence global biotech sector perceptions.

Counterpoint

Some investors may view the spin-off as a sign of internal challenges or strategic retreat, leading to potential short-term volatility.

Key entities

  • FOXO Technologies Inc.

    A biotech company listed on NYSE American, focusing on health and wellness technologies.

  • FOXO Labs, Inc.

    A subsidiary focused on epigenetics research and development.

Related articles

$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.